Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis |
Zhang, Wen-Ying
(Department of Gastroenterology, Changhai Hospital, Second Military Medical University)
Zhang, Wen-Jun (Department of Gerontology, Changhai Hospital, Second Military Medical University) Bai, Yu (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Yuan, Hai-Hua (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) Liu, Feng (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) Gao, Jun (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Gong, Yan-Fang (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Jiang, Bin (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) |
1 | Neri B, Pantaleo P, Giommoni E, et al (2007). Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer, 96, 1043-6. DOI ScienceOn |
2 | Oba K (2009). Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol, 14, 85-9. DOI |
3 | Oh SC (2012). Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer, 12, 3-6. DOI ScienceOn |
4 | Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-55. DOI ScienceOn |
5 | Okines A, Verheij M, Allum W, et al (2010). Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v50-4. DOI ScienceOn |
6 | Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7. |
7 | Paoletti X, Oba K, Burzykowski T, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303, 1729-37. DOI ScienceOn |
8 | Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20. DOI ScienceOn |
9 | Saletti P, Berthold D, Ghielmini M, et al (2007). Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. Hepatogastroenterology, 54, 969-72. |
10 | Sasako M, Sakuramoto S, Katai H, et al (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29, 4387-93. DOI ScienceOn |
11 | Zhang CX, Huang S, Xu N, et al (2007). Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Anticancer Drugs, 18, 581-6. DOI ScienceOn |
12 | Zhao SL, Fang JY (2008). The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest, 26, 317-25. DOI ScienceOn |
13 | Bang YJ, Kim YW, Yang HK, et al (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 379, 315-21. DOI ScienceOn |
14 | Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20. DOI ScienceOn |
15 | Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. DOI ScienceOn |
16 | Degiuli M, Calvo F (2006). Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg, 30, 2193-203. DOI |
17 | De Vita F, Giuliani F, Orditura M, et al (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol, 18, 1354-8. DOI ScienceOn |
18 | Jeen YT, Yoon SY, Shin SW, et al (2001). Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer, 91, 2288-93. DOI ScienceOn |
19 | Di Costanzo F, Gasperoni S, Manzione L, et al (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst, 100, 388-98. DOI ScienceOn |
20 | Dikken JL, Jansen EP, Cats A, et al (2010). Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol, 28, 2430-6. DOI ScienceOn |
21 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
22 | Kang BW, Kim JG, Chae YS, et al (2011). Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs, 30, 1671-5. |
23 | Karacetin D, Incekara O (2004). A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas. J BUON, 9, 263-7. |
24 | Kim DH, Oh CA, Oh SJ, et al (2012). Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol, 105, 26-30. DOI ScienceOn |
25 | Kulig J, Kolodziejczyk P, Sierzega M, et al (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78, 54-61. DOI ScienceOn |
26 | Lim L, Michael M, Mann GB, et al (2005). Adjuvant therapy in gastric cancer. J Clin Oncol, 23, 6220-32. DOI ScienceOn |
27 | Aoyama T, Yoshikawa T, Watanabe T, et al (2011). Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer, 14, 150-4. DOI |
28 | Moon YW, Jeung HC, Rha SY, et al (2007). Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol, 14, 2730-7. DOI |
![]() |